GLP-1 & Incretin Science

GDF15: The Same Signal, Wanted and Feared

UKPWritten and published by UK Peptides4 min readUpdated 4 cited sources

The short answer

GDF15 is a circulating protein of the TGF-beta superfamily that suppresses food intake by acting on GFRAL, a receptor confined to the hindbrain. The same signal drives wasting in cachexia and nausea in pregnancy, so it is being targeted in opposite directions at once.

Key facts

Full name
Growth differentiation factor 15; also MIC-1
Family
TGF-beta superfamily
Receptor
GFRAL, GDNF family receptor alpha-like
Receptor location
Neurons of the hindbrain / brainstem
Receptor identified
2017; the field had no receptor before that
Direction of effect
Suppresses food intake
Raised in
Cancer, chronic renal failure, cardiac failure, COPD, pregnancy
Also raised by
Metformin

A hormone the field could not work on for years

GDF15 was known to affect energy balance long before anyone knew how. As a review by Mullican and Rangwala put it, the potential to target it in energy-intake disorders was an area of intense investigation but had been limited by the lack of an identified receptor, signalling mechanism and target tissue. That is an unusual position for a drug target: an effect with no known route. The situation changed in 2017, when GFRAL was identified as the neuronal brainstem receptor responsible for mediating GDF15's anorectic actions. Four groups reported the work at roughly the same time, which is itself a sign of how hard the field was pushing at the question.

Why GFRAL's location is the whole story

GFRAL is not distributed broadly. It is confined to neurons of the hindbrain, in the region where the blood-brain barrier is permeable and circulating signals about the internal state of the body are read. That is the same neighbourhood as the area postrema, the structure that also mediates the aversive component of GLP-1 receptor agonism. A receptor that exists in one small brainstem population and almost nowhere else is an unusually clean drug target in one sense (off-target tissue effects are structurally unlikely) and a difficult one in another, because that population's job is to make an animal stop eating and, if the signal is strong enough, to make it feel sick.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

The metformin connection, and the knockout that proved it

One of the more surprising findings about GDF15 concerns a drug that has been in use since the 1950s. Day and colleagues showed that metformin induces expression and secretion of GDF15 from hepatocytes, working through the transcription factors ATF4 and CHOP. In wild-type mice on a high-fat diet, oral metformin raised serum GDF15 and reduced food intake, body mass, fasting insulin and glucose intolerance. In GDF15-null mice, those effects were eliminated. An increase in serum GDF15 was also associated with weight loss in patients with type 2 diabetes taking metformin. The modest weight effect of the oldest drug in diabetes may therefore run through the newest appetite pathway in obesity, and the knockout is what turns that from a correlation into a mechanism.

The same molecule, wanted from both directions

This is what makes GDF15 unlike any other target in this field. Raising it suppresses appetite, which is the obesity thesis. But GDF15 is also substantially elevated in cachexia, and Tsai and colleagues note that the elevated serum levels seen in cancer, chronic renal failure, cardiac failure and chronic obstructive lung disease are similar to those required to induce the anorexia/cachexia syndrome in animals, where its brainstem action produces prolonged undernutrition and loss of both lean and fat mass. Their conclusion is that inhibiting GDF15 or GFRAL is a high-value target. So one set of programmes is trying to agonise this pathway and another is trying to block it, and both are looking at the same evidence. The two positions are compatible, because the signal behaves like a dial rather than a switch.

The finding that should worry anyone building a chronic agonist

The most consequential piece of GDF15 pharmacology for obesity came out of a pregnancy paper. Fejzo and colleagues reported in Nature that the great majority of GDF15 in maternal plasma derives from the feto-placental unit, and that maternal sensitivity to it is a major determinant of how sick a pregnancy makes someone. Two of their results run against intuition. Low levels of GDF15 in the non-pregnant state increase the risk of hyperemesis gravidarum. And women with beta-thalassaemia, in whom GDF15 is chronically high, report very low levels of nausea and vomiting in pregnancy. In mice, the acute food-intake response to a GDF15 bolus was influenced bi-directionally by prior circulating levels in a way the authors describe as suggesting the system is susceptible to desensitisation. A pathway that becomes less responsive the more it has been exposed has the wrong property for a drug intended to be taken indefinitely.

Where this leaves the target

GDF15 has an identified receptor in a defined location, a genetic proof of concept through the metformin work, a human phenotype in both directions, and a plausible desensitisation problem. That combination makes it one of the most interesting non-incretin targets and one of the least certain. No GDF15 or GFRAL agent is licensed anywhere for any indication. Nothing described here is supplied on this site, and none of it is a treatment for anything.

Frequently asked questions

Is GDF15 a peptide like the incretins?

No. It is a protein of the TGF-beta superfamily, considerably larger than a peptide hormone, and it acts on a receptor complex rather than a class B GPCR. Grouping it with GLP-1 because both reduce appetite through the hindbrain obscures how different the molecules and the receptors are.

If metformin raises GDF15, why is metformin's weight effect small?

Because the increase is modest compared with what a purpose-built agonist would produce, and because weight loss is only one of metformin's actions. The finding explains part of an effect that was previously unexplained; it does not make metformin an appetite drug.

Does the desensitisation finding rule out GDF15 agonists?

No, but it raises a specific and testable objection. The mouse data concerns an acute food-intake response after prior exposure, and the human observation is an association in an unusual population. What it establishes is that anyone developing a chronic agonist has to demonstrate durability rather than assume it.

Why would a fetus produce a hormone that makes the mother sick?

That question is not settled and the paper does not claim to answer it. The finding is that the hormone is largely fetal in origin and that maternal sensitivity determines severity. Speculating about why is a different exercise from establishing that it happens.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More GLP-1 & Incretin Science articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.